European study of COVID-19 vaccine effectiveness against hospitalised SARI patients laboratory-confirmed with SARS-CoV-2 (I-MOVE-COVID VE hospital study)

27/02/2021
14/03/2024
EU PAS number:
EUPAS39683
Study
Planned
Study type

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Case-control
Population studied

Age groups

  • Children (2 to < 12 years)
  • Adolescents (12 to < 18 years)
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

1000
Study design details

Main study objective

To measure product-specific COVID-19 vaccine effectiveness

Outcomes

SARI laboratory confirmed as COVID-19 / SARS-CoV-2 infection, SARS-CoV-2 variant specific

Data analysis plan

Test-negative design. Vaccine effectiveness: adjusted 1-OR*100 Study site as fixed effect. Time adjusted. Stratification by age group, chronic condition. Vaccine effectiveness over time.